Immune therapy for treating type 1 diabetes

Challenging existing paradigms

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Patients with type 1 diabetes (T1D) rapidly lose β cell function and/or mass, leading to a life-long dependence on insulin therapy. β Cell destruction is mediated by aberrant immune responses; therefore, immune modulation has potential to ameliorate disease. While immune intervention in animal models of diabetes has shown promising results, treatment of patients with T1D with the same agents has not been as successful. In this issue of the JCI, Haller and colleagues present data from a small clinical trial that tested the efficacy of a combination of immunomodulatory agents, anti-thymocyte globulin and pegylated granulocyte CSF, neither of which have shown benefit for T1D as single treatment agents. Many patients that received combination therapy maintained β cell function at baseline levels up to a year after treatment. The results from this study challenge current trial design paradigm that for combined therapy to be successful individual agents should show benefit.

Original languageEnglish
Pages (from-to)94-96
Number of pages3
JournalJournal of Clinical Investigation
Volume125
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Type 1 Diabetes Mellitus
Therapeutics
Antilymphocyte Serum
Cell- and Tissue-Based Therapy
Granulocytes
Animal Models
Clinical Trials
Insulin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immune therapy for treating type 1 diabetes : Challenging existing paradigms. / Skyler, Jay S.

In: Journal of Clinical Investigation, Vol. 125, No. 1, 01.01.2015, p. 94-96.

Research output: Contribution to journalArticle

@article{c36abba95020463b8068639c80decbda,
title = "Immune therapy for treating type 1 diabetes: Challenging existing paradigms",
abstract = "Patients with type 1 diabetes (T1D) rapidly lose β cell function and/or mass, leading to a life-long dependence on insulin therapy. β Cell destruction is mediated by aberrant immune responses; therefore, immune modulation has potential to ameliorate disease. While immune intervention in animal models of diabetes has shown promising results, treatment of patients with T1D with the same agents has not been as successful. In this issue of the JCI, Haller and colleagues present data from a small clinical trial that tested the efficacy of a combination of immunomodulatory agents, anti-thymocyte globulin and pegylated granulocyte CSF, neither of which have shown benefit for T1D as single treatment agents. Many patients that received combination therapy maintained β cell function at baseline levels up to a year after treatment. The results from this study challenge current trial design paradigm that for combined therapy to be successful individual agents should show benefit.",
author = "Skyler, {Jay S}",
year = "2015",
month = "1",
day = "1",
doi = "10.1172/JCI79190",
language = "English",
volume = "125",
pages = "94--96",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Immune therapy for treating type 1 diabetes

T2 - Challenging existing paradigms

AU - Skyler, Jay S

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Patients with type 1 diabetes (T1D) rapidly lose β cell function and/or mass, leading to a life-long dependence on insulin therapy. β Cell destruction is mediated by aberrant immune responses; therefore, immune modulation has potential to ameliorate disease. While immune intervention in animal models of diabetes has shown promising results, treatment of patients with T1D with the same agents has not been as successful. In this issue of the JCI, Haller and colleagues present data from a small clinical trial that tested the efficacy of a combination of immunomodulatory agents, anti-thymocyte globulin and pegylated granulocyte CSF, neither of which have shown benefit for T1D as single treatment agents. Many patients that received combination therapy maintained β cell function at baseline levels up to a year after treatment. The results from this study challenge current trial design paradigm that for combined therapy to be successful individual agents should show benefit.

AB - Patients with type 1 diabetes (T1D) rapidly lose β cell function and/or mass, leading to a life-long dependence on insulin therapy. β Cell destruction is mediated by aberrant immune responses; therefore, immune modulation has potential to ameliorate disease. While immune intervention in animal models of diabetes has shown promising results, treatment of patients with T1D with the same agents has not been as successful. In this issue of the JCI, Haller and colleagues present data from a small clinical trial that tested the efficacy of a combination of immunomodulatory agents, anti-thymocyte globulin and pegylated granulocyte CSF, neither of which have shown benefit for T1D as single treatment agents. Many patients that received combination therapy maintained β cell function at baseline levels up to a year after treatment. The results from this study challenge current trial design paradigm that for combined therapy to be successful individual agents should show benefit.

UR - http://www.scopus.com/inward/record.url?scp=84920423350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920423350&partnerID=8YFLogxK

U2 - 10.1172/JCI79190

DO - 10.1172/JCI79190

M3 - Article

VL - 125

SP - 94

EP - 96

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -